AxoGen’s (AXGN) Overweight Rating Reaffirmed at Cantor Fitzgerald

Share on StockTwits

AxoGen (NASDAQ:AXGN)‘s stock had its “overweight” rating reissued by equities research analysts at Cantor Fitzgerald in a research report issued on Thursday, The Fly reports. They currently have a $30.00 price target on the medical equipment provider’s stock, up from their previous price target of $26.00. Cantor Fitzgerald’s price target would indicate a potential upside of 30.32% from the stock’s current price.

AXGN has been the topic of several other research reports. ValuEngine upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Wednesday, May 1st. BTIG Research upgraded shares of AxoGen from a “neutral” rating to a “buy” rating and set a $28.00 price target on the stock in a research note on Monday, March 25th. Finally, BidaskClub upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Wednesday, March 6th. Five investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average price target of $37.67.

Shares of AXGN opened at $23.02 on Thursday. AxoGen has a 12 month low of $14.13 and a 12 month high of $56.85. The firm has a market cap of $973.50 million, a PE ratio of -42.63 and a beta of 0.20.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings results on Wednesday, May 8th. The medical equipment provider reported ($0.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.05. AxoGen had a negative net margin of 26.68% and a negative return on equity of 15.77%. The company had revenue of $23.30 million for the quarter, compared to analyst estimates of $22.33 million. During the same quarter in the prior year, the business posted ($0.11) EPS. AxoGen’s quarterly revenue was up 34.7% on a year-over-year basis. Research analysts forecast that AxoGen will post -0.61 earnings per share for the current year.

A number of large investors have recently bought and sold shares of AXGN. Quantamental Technologies LLC increased its position in shares of AxoGen by 108.3% during the 1st quarter. Quantamental Technologies LLC now owns 1,431 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 744 shares in the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in AxoGen during the 4th quarter valued at approximately $77,000. NumerixS Investment Technologies Inc acquired a new stake in AxoGen during the 4th quarter valued at approximately $131,000. BNP Paribas Arbitrage SA increased its position in AxoGen by 8,717.5% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,054 shares of the medical equipment provider’s stock valued at $149,000 after purchasing an additional 6,974 shares during the period. Finally, Citigroup Inc. increased its position in AxoGen by 17.4% during the 4th quarter. Citigroup Inc. now owns 9,905 shares of the medical equipment provider’s stock valued at $202,000 after purchasing an additional 1,467 shares during the period. Institutional investors and hedge funds own 89.10% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Recommended Story: The Role of a Fiduciary and Individual Investors

The Fly

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.